D61.810

Antineoplastic chemotherapy induced pancytopenia

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC ESRD V24

HCC47

Disorders of Immunity

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

This code · D61.810
Excludes 2

aplastic anemia due to antineoplastic chemotherapy (D61.1)

Inherited from D61.81Pancytopenia
Excludes 1

pancytopenia (due to) (with) aplastic anemia (D61.9) pancytopenia (due to) (with) bone marrow infiltration (D61.82) pancytopenia (due to) (with) congenital (pure) red cell aplasia (D61.01) pancytopenia (due to) (with) hairy cell leukemia (C91.4-) pancytopenia (due to) (with) human immunodeficiency virus disease (B20.-) pancytopenia (due to) (with) leukoerythroblastic anemia (D61.82) pancytopenia (due to) (with) myeloproliferative disease (D47.1)

Excludes 2

pancytopenia (due to) (with) myelodysplastic syndromes (D46.-)

Inherited from D61Oth aplastic anemias and other bone marrow failure syndromes
Excludes 2

neutropenia (D70.-)

Inherited from chapter 3Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Excludes 2

autoimmune disease (systemic) NOS (M35.9) certain conditions originating in the perinatal period (P00-P96) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) human immunodeficiency virus [HIV] disease (B20) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)

Official Guidelines for D61.810

FY 2026 ›

Find D61.810 in the alphabetic index

1 index path leads to this code